Press "Enter" to skip to content

New patent for Astrazeneca Ab drug QTERN

1
Copyright © DrugPatentWatch. Originally published at New patent for Astrazeneca Ab drug QTERN

Annual Drug Patent Expirations for QTERN
Annual Drug Patent Expirations for QTERN

Qtern is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are twelve patents protecting this drug and one Paragraph IV challenge.

QTERN drug price trends.

Drug patent litigation for QTERN.

This drug has three hundred and thirty-one patent family members in forty-seven countries.

The generic ingredient in QTERN is dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride. One supplier is listed for this compound. Additional details are available on the dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at New patent for Astrazeneca Ab drug QTERN
DrugPatentWatch - Make Better Decisions